CA2270469C - Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques - Google Patents
Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques Download PDFInfo
- Publication number
- CA2270469C CA2270469C CA002270469A CA2270469A CA2270469C CA 2270469 C CA2270469 C CA 2270469C CA 002270469 A CA002270469 A CA 002270469A CA 2270469 A CA2270469 A CA 2270469A CA 2270469 C CA2270469 C CA 2270469C
- Authority
- CA
- Canada
- Prior art keywords
- pyrazol
- alkyl
- benzenesulfonamide
- trifluoromethyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Abstract
L'invention concerne l'utilisation d'inhibiteurs de cyclo-oxygénase-2 ou de leurs dérivés pour prévenir ou traiter des troubles liés à l'angiogenèse.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3140496P | 1996-11-19 | 1996-11-19 | |
US60/031,404 | 1996-11-19 | ||
PCT/US1997/021489 WO1998022101A2 (fr) | 1996-11-19 | 1997-11-19 | Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2270469A1 CA2270469A1 (fr) | 1998-05-28 |
CA2270469C true CA2270469C (fr) | 2007-04-10 |
Family
ID=21859277
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002270469A Expired - Fee Related CA2270469C (fr) | 1996-11-19 | 1997-11-19 | Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques |
Country Status (19)
Country | Link |
---|---|
EP (1) | EP0941080A2 (fr) |
JP (1) | JP2001505564A (fr) |
KR (1) | KR20000053362A (fr) |
CN (1) | CN1247470A (fr) |
AU (1) | AU730211B2 (fr) |
BR (1) | BR9713522A (fr) |
CA (1) | CA2270469C (fr) |
CZ (1) | CZ176899A3 (fr) |
ID (1) | ID21979A (fr) |
IL (1) | IL129604A (fr) |
NO (1) | NO992309L (fr) |
NZ (1) | NZ335853A (fr) |
PL (2) | PL194717B1 (fr) |
RO (1) | RO118566B1 (fr) |
RU (1) | RU2268716C2 (fr) |
SK (1) | SK59999A3 (fr) |
TR (1) | TR199901703T2 (fr) |
UA (1) | UA70294C2 (fr) |
WO (1) | WO1998022101A2 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6515014B2 (en) | 1995-06-02 | 2003-02-04 | G. D. Searle & Co. | Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
US6512121B2 (en) | 1998-09-14 | 2003-01-28 | G.D. Searle & Co. | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors |
NZ333399A (en) | 1997-12-24 | 2000-05-26 | Sankyo Co | Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis |
US20030013739A1 (en) * | 1998-12-23 | 2003-01-16 | Pharmacia Corporation | Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia |
US6833373B1 (en) | 1998-12-23 | 2004-12-21 | G.D. Searle & Co. | Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia |
IL143901A0 (en) * | 1998-12-23 | 2002-04-21 | Searle & Co | Use of cyclooxygenase-2- inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia |
EP1637137A3 (fr) * | 1999-03-10 | 2006-07-05 | G.D. Searle LLC | Méthode et composition se rapportant à l'administration d'un inhibiteure de la cyclooxygénase-2 aux animaux |
EP1206256B8 (fr) * | 1999-07-29 | 2005-06-29 | Amgen, Inc. | Therapie d'association comprenant l'administration de pentafluorobenzenesulfonamides |
JP4371295B2 (ja) | 2000-05-19 | 2009-11-25 | メルク セローノ ソシエテ アノニム | 医薬として活性な化合物およびその使用方法 |
WO2002039958A2 (fr) | 2000-11-03 | 2002-05-23 | Tularik Inc. | Therapies combinees a base de pentafluorobenzenesulfonamides et d'agents antineoplasiques |
KR100686537B1 (ko) * | 2001-12-28 | 2007-02-27 | 씨제이 주식회사 | 사이클로옥시게나제-2 의 저해제로서 선택성이 뛰어난디아릴 1,2,4-트리아졸 유도체 |
AU2003281170A1 (en) * | 2002-07-17 | 2004-02-02 | Warner-Lambert Company Llc | Pharmaceutical compostions comprising an allosteric carboxylic inhibitor of matrix metalloproteinase-13 and a selective inhibitor of cyclooxygenase-2 |
KR100484525B1 (ko) * | 2002-10-15 | 2005-04-20 | 씨제이 주식회사 | 이소티아졸 유도체, 그 제조방법 및 약제학적 조성물 |
AT504159A1 (de) * | 2006-08-16 | 2008-03-15 | Marlyn Nutraceuticals Inc | Verwendung von proteasen |
RU2475257C1 (ru) * | 2011-06-22 | 2013-02-20 | Людмила Николаевна Третьяк | Средство для повышения адаптируемости организма к экстремальным условиям |
GB2496135B (en) * | 2011-11-01 | 2015-03-18 | Valirx Plc | Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994015932A1 (fr) * | 1993-01-15 | 1994-07-21 | G.D. Searle & Co. | Nouveaux thiophenes 3,4-diaryle et leurs analogues utilises comme agents anti-inflammatoires |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
CA2276945C (fr) * | 1993-11-30 | 2006-08-01 | G.D. Searle & Co. | Pyrazolyle benzenesulfonamide tricyclique-substitue et leurs compositions pharmaceutiques |
US5521213A (en) * | 1994-08-29 | 1996-05-28 | Merck Frosst Canada, Inc. | Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 |
JPH10511089A (ja) * | 1994-12-21 | 1998-10-27 | メルク フロスト カナダ インコーポレーテツド | Cox−2阻害剤としてのジアリール−2−(5h)−フラノン |
US5691374A (en) * | 1995-05-18 | 1997-11-25 | Merck Frosst Canada Inc. | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
-
1997
- 1997-11-19 AU AU72982/98A patent/AU730211B2/en not_active Ceased
- 1997-11-19 EP EP97949579A patent/EP0941080A2/fr not_active Withdrawn
- 1997-11-19 UA UA99063447A patent/UA70294C2/uk unknown
- 1997-11-19 RO RO99-00572A patent/RO118566B1/ro unknown
- 1997-11-19 WO PCT/US1997/021489 patent/WO1998022101A2/fr not_active Application Discontinuation
- 1997-11-19 CA CA002270469A patent/CA2270469C/fr not_active Expired - Fee Related
- 1997-11-19 TR TR1999/01703T patent/TR199901703T2/xx unknown
- 1997-11-19 KR KR1019990704392A patent/KR20000053362A/ko not_active Application Discontinuation
- 1997-11-19 IL IL12960497A patent/IL129604A/en not_active IP Right Cessation
- 1997-11-19 PL PL97373973A patent/PL194717B1/pl unknown
- 1997-11-19 JP JP52396098A patent/JP2001505564A/ja not_active Withdrawn
- 1997-11-19 SK SK599-99A patent/SK59999A3/sk unknown
- 1997-11-19 CN CN97181368A patent/CN1247470A/zh active Pending
- 1997-11-19 NZ NZ335853A patent/NZ335853A/en not_active Application Discontinuation
- 1997-11-19 CZ CZ991768A patent/CZ176899A3/cs unknown
- 1997-11-19 ID IDW990379A patent/ID21979A/id unknown
- 1997-11-19 RU RU99112952/14A patent/RU2268716C2/ru not_active IP Right Cessation
- 1997-11-19 BR BR9713522A patent/BR9713522A/pt not_active Application Discontinuation
-
1999
- 1999-04-30 PL PL333370A patent/PL191793B1/pl unknown
- 1999-05-12 NO NO992309A patent/NO992309L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2270469A1 (fr) | 1998-05-28 |
TR199901703T2 (xx) | 2000-07-21 |
PL191793B1 (pl) | 2006-07-31 |
NO992309D0 (no) | 1999-05-12 |
SK59999A3 (en) | 2000-01-18 |
PL194717B1 (pl) | 2007-06-29 |
EP0941080A2 (fr) | 1999-09-15 |
IL129604A (en) | 2004-08-31 |
JP2001505564A (ja) | 2001-04-24 |
RO118566B1 (ro) | 2003-07-30 |
CN1247470A (zh) | 2000-03-15 |
ID21979A (id) | 1999-08-19 |
AU7298298A (en) | 1998-06-10 |
KR20000053362A (ko) | 2000-08-25 |
PL333370A1 (en) | 1999-12-06 |
AU730211B2 (en) | 2001-03-01 |
BR9713522A (pt) | 2000-03-21 |
IL129604A0 (en) | 2000-02-29 |
NO992309L (no) | 1999-05-12 |
RU2268716C2 (ru) | 2006-01-27 |
CZ176899A3 (cs) | 1999-10-13 |
WO1998022101A2 (fr) | 1998-05-28 |
WO1998022101A3 (fr) | 1998-06-25 |
NZ335853A (en) | 2002-02-01 |
UA70294C2 (en) | 2004-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6025353A (en) | Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents | |
US5972986A (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | |
AU742645B2 (en) | Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia | |
WO1998016227A9 (fr) | Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique | |
CA2270469C (fr) | Procede d'utilisation d'inhibiteurs de cyclo-oxygenase-2 comme agents anti-angiogeniques | |
CA2372912C (fr) | Application d'inhibiteurs de la cyclogenase-2 au traitement et a la prevention du processus neoplasique | |
IL154502A (en) | Use of cyclooxygenase-2 inhibitors in the preparation of medicaments for treating angiogenesis-related disorders | |
NZ517374A (en) | Method of using cycloozygenase-2 inhibitors to prevent a neoplasia that produces a prostaglandin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |